Cardiff Oncology Inc (CRDF) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cardiff Oncology Inc (CRDF) has a cash flow conversion efficiency ratio of -0.131x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.97 Million) by net assets ($45.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CRDF defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Cardiff Oncology Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Cardiff Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cardiff Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cardiff Oncology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ratchaphruek Hospital Public Company Limited
BK:RPH
|
0.046x |
|
Ares International Corp
TW:2471
|
0.142x |
|
Scully Royalty Ltd
F:MB01
|
0.026x |
|
PRL Global Ltd
AU:PRG
|
0.097x |
|
DPSC Limited
NSE:DPSCLTD
|
0.058x |
|
Gray Television Inc
NYSE:GTN-A
|
0.000x |
|
Silvercrest Asset Management Group Inc
NASDAQ:SAMG
|
0.175x |
|
Kjell Group AB
ST:KJELL
|
0.245x |
Annual Cash Flow Conversion Efficiency for Cardiff Oncology Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Cardiff Oncology Inc from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see CRDF company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $45.39 Million | $-37.92 Million | -0.836x | -83.87% |
| 2024-12-31 | $82.95 Million | $-37.69 Million | -0.454x | -2.60% |
| 2023-12-31 | $69.74 Million | $-30.89 Million | -0.443x | -39.26% |
| 2022-12-31 | $106.34 Million | $-33.82 Million | -0.318x | -93.82% |
| 2021-12-31 | $140.42 Million | $-23.04 Million | -0.164x | -28.89% |
| 2020-12-31 | $128.16 Million | $-16.31 Million | -0.127x | +92.98% |
| 2019-12-31 | $7.31 Million | $-13.27 Million | -1.815x | -38.63% |
| 2018-12-31 | $10.08 Million | $-13.20 Million | -1.309x | +63.42% |
| 2017-12-31 | $6.51 Million | $-23.28 Million | -3.578x | -127.89% |
| 2016-12-31 | $19.77 Million | $-31.04 Million | -1.570x | -245.73% |
| 2015-12-31 | $48.70 Million | $-22.12 Million | -0.454x | +70.21% |
| 2014-12-31 | $8.35 Million | $-12.73 Million | -1.524x | -324.83% |
| 2013-12-31 | $20.39 Million | $-7.32 Million | -0.359x | +84.23% |
| 2012-12-31 | $2.17 Million | $-4.93 Million | -2.275x | -598.70% |
| 2011-12-31 | $-4.23 Million | $-1.93 Million | 0.456x | +9.10% |
| 2010-12-31 | $-5.00 Million | $-2.09 Million | 0.418x | +28.84% |
| 2009-12-31 | $-3.79 Million | $-1.23 Million | 0.325x | -- |
About Cardiff Oncology Inc
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in… Read more